Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.

NCT02352675 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.

NCT NCT02352675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02352675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.
Lead sponsor
Boston Children's Hospital
Phase
Observational
Overall status
Completed
Start date
April 30, 2015
Completion date
March 31, 2016
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital heart disease, fibrinolysis, rotational thromboelastometry